Gilead SciencesGILD
GILD
About: Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Employees: 17,600
0
Funds holding %
of 7,295 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
149% more first-time investments, than exits
New positions opened: 274 | Existing positions closed: 110
79% more funds holding in top 10
Funds holding in top 10: 28 [Q4 2024] → 50 (+22) [Q1 2025]
18% more capital invested
Capital invested by funds: $98.3B [Q4 2024] → $116B (+$18B) [Q1 2025]
6% more funds holding
Funds holding: 1,852 [Q4 2024] → 1,965 (+113) [Q1 2025]
0% more call options, than puts
Call options by funds: $1.2B | Put options by funds: $1.19B
1.79% less ownership
Funds ownership: 85.16% [Q4 2024] → 83.37% (-1.79%) [Q1 2025]
17% less repeat investments, than reductions
Existing positions increased: 672 | Existing positions reduced: 806
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$117
4%
upside
Avg. target
$125
12%
upside
High target
$135
20%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
Mizuho Salim Syed | 4%upside $117 | Outperform Maintained | 5 May 2025 |
Oppenheimer Hartaj Singh | 12%upside $125 | Outperform Maintained | 25 Apr 2025 |
Morgan Stanley Matthew Harrison | 20%upside $135 | Overweight Maintained | 25 Apr 2025 |
Cantor Fitzgerald Carter Gould | 12%upside $125 | Overweight Assumed | 22 Apr 2025 |
BMO Capital Evan Seigerman | 7%upside $120 | Outperform Maintained | 17 Apr 2025 |
Financial journalist opinion
Based on 36 articles about GILD published over the past 30 days
Neutral
Accesswire
10 hours ago
ATTENTION GILD Investors: Securities Fraud Investigation Underway - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / June 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Gilead Sciences, Inc. ("Gilead Sciences, Inc.") (NASDAQ:GILD) concerning possible violations of federal securities laws. Gilead issued a press release on June 10, 2025, announcing that "[t]he U.S. Food and Drug Administration has placed a clinical hold on Gilead's HIV treatment trials of GS-1720 (an investigational integrase strand transfer inhibitor) and/or GS-4182 (an investigational capsid inhibitor)[,]" specifying that "[t]he clinical hold is due to the identification of a safety signal of decreases in CD4+T-cell (CD4) and absolute lymphocyte counts in a subset of participants receiving the combination of GS-1720 and GS-4182.
Neutral
Accesswire
11 hours ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Gilead Sciences, Inc. (GILD) And Encourages Stockholders to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gilead Sciences, Inc. ("Gilead" or "the Company") (NASDAQ:GILD). Investors who purchased Gilead securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/GILD.
Positive
Zacks Investment Research
13 hours ago
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Neutral
Accesswire
1 day ago
Levi & Korsinsky Investigates Possible Securities Fraud by Gilead Sciences, Inc. (GILD)
NEW YORK, NY / ACCESS Newswire / June 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Gilead Sciences, Inc. ("Gilead Sciences, Inc.") (NASDAQ:GILD) concerning possible violations of federal securities laws. Gilead issued a press release on June 10, 2025, announcing that "[t]he U.S. Food and Drug Administration has placed a clinical hold on Gilead's HIV treatment trials of GS-1720 (an investigational integrase strand transfer inhibitor) and/or GS-4182 (an investigational capsid inhibitor)[,]" specifying that "[t]he clinical hold is due to the identification of a safety signal of decreases in CD4+T-cell (CD4) and absolute lymphocyte counts in a subset of participants receiving the combination of GS-1720 and GS-4182.
Neutral
Accesswire
1 day ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
NEW YORK CITY, NY / ACCESS Newswire / June 11, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or the "Company") (NASDAQ:GILD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Negative
Zacks Investment Research
1 day ago
FDA Places Clinical Hold on Gilead's HIV Studies, Stock Down
GILD slides 2.6% after FDA halts trials for HIV candidates, GS-1720 and GS-4182, over safety concerns in patients.
Positive
Zacks Investment Research
1 day ago
Is It Worth Investing in Gilead (GILD) Based on Wall Street's Bullish Views?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Negative
The Motley Fool
2 days ago
Why Gilead Scinces Stock Tumbled on Tuesday
On some negative news about one of its investigational programs, the stock of pharmaceutical company Gilead Sciences (GILD -2.54%) took some hits on Tuesday. Investors traded it down by more than 2%, comparing unfavorably to the 0.6% gain of the benchmark S&P 500 (^GSPC 0.55%).
Neutral
Seeking Alpha
2 days ago
Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Gilead Sciences, Inc. (NASDAQ:GILD ) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 11:20 AM ET Company Participants Daniel P. O'Day - Chairman & CEO Conference Call Participants Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division Salveen Jaswal Richter Great.
Negative
Proactive Investors
2 days ago
Gilead shares fall after FDA places clinical hold on HIV treatment trials
Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS) dropped up to 4% on Tuesday following an announcement that the US Food and Drug Administration (FDA) has placed clinical holds on studies involving two of the company's investigational HIV drugs. The FDA's clinical hold affects trials of GS-1720, an integrase strand transfer inhibitor, and GS-4182, a capsid inhibitor.
Charts implemented using Lightweight Charts™